Carisma Therapeutics (CARM) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights Initial results from the Phase 1 study of CT-0525, lead product candidate, expected in the first quarter of 2025 Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025 New preclinical ef icacy data from the anti-GPC3 in vivo CAR-M therapy to be presented on November 8 at SITC 2024 Annual Meeting New preclinical ef icacy data in liver fibrosis to be pre ...